Skip to main content
SpringerLink
Log in

In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates ofHelicobacter pylori

  • Note
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The aim of this study was to determine the in vitro activity of ranitidine, ebrotidine, bismuth citrate, omeprazole, and lansoprazole against 113 clinical isolates ofHelicobacter pylori cultured from gastric biopsies. An agar dilution method using Mueller-Hinton agar plus 7% horse blood, an inoculum of 106 cfu/spot, and incubation in a CO2 incubator for 2 to 5 days was used. The minimum inhibitory concentrations for 50 and 90% of the isolates tested, respectively, were as follows: ranitidine, 1024 and 1024 mg/l; ebrotidine, 64 and 256 mg/1; bismuth citrate, 1 and 4 mg/l; omeprazole, 16 and 16 mg/1; and lansoprazole, 1 and 1 mg/l. Ebrotidine was more active than ranitidine, and lansoprazole was the most active compound against theHelicobacter pylori isolates tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marshall BJ:Campylobacter pylori: its link to gastritis and peptic ulcer disease. Reviews of Infectious Diseases (1990) 12:587–593.

    Google Scholar 

  2. International Agency for Research on Cancer: Schistosomas, liver flukes andHelicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 61. WHO Publications, Geneva (1994) p. 270.

    Google Scholar 

  3. Labenz J, O'Morain C: Eradication. The year inHelicobacter pylori 1995. Current Opinion in Gastroenterology (1995) 11, Supplement 1:47–51.

    Google Scholar 

  4. Korman, MG:Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors. Scandinavian Journal of Gastroenterology (1996) 220, Supplement:41–43.

    Google Scholar 

  5. Lambert JR, Midolo P: The actions of bismuth in the treatment ofHelicobacter pylori infection. Alimentary Pharmacology and Therapeutics (1997) 11, Supplement 1:27–33.

    PubMed  Google Scholar 

  6. Wilde MI, McTavish D: Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs (1994) 48:91–132.

    PubMed  Google Scholar 

  7. Dickey W, Kenny BD, McConnell JB: Effect of proton pump inhibitors on the detection ofHelicobacter pylori in gastric biopsies. Alimentary Pharmacology and Therapeutics (1996) 10:289–293.

    PubMed  Google Scholar 

  8. Alarcón T, Domingo D, Sanchez I, Diaz de Rojas F, López-Brea M: In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates ofHelicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:937–940.

    Google Scholar 

  9. Roine RP, Salmela KS, Hook-Nikanne J, Kosunen TU, Salaspuro M: Colloidal bismuth subcitrate and omeprazole inhibit alcohol dehydrogenase mediated acetaldehyde production byHelicobacter pylori. Life Sciences (1992) 51:195–200.

    PubMed  Google Scholar 

  10. Patel SS, Wilde MI: Ebrotidine. Drugs (1996) 51:974–980.

    PubMed  Google Scholar 

  11. Piotrowski J, Slomiany A, Slomiany BL: Inhibition ofHelicobacter pylori urease activity by ebrotidine. Biochemistry and Molecular Biology International (1995) 37:247–253.

    PubMed  Google Scholar 

  12. Piotrowski J, Piotrowski E, Slomiany A, Slomiany BL: Susceptibility ofHelicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine. Journal of Physiology and Pharmacology (1995) 46:463–469.

    PubMed  Google Scholar 

  13. Mears JM, Kaplan B: Proton pump inhibitors: new drugs and indications. American Family Physician (1996) 53:285–292.

    PubMed  Google Scholar 

  14. Figura N, Crabtree JE, Dattilo M: In vitro activity of lansoprazole againstHelicobacter pylori. Journal of Antimicrobial Chemotherapy (1997) 39:585–590.

    PubMed  Google Scholar 

  15. Nakao M, Tada M, Tsuchimori K, Uekata M: Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents againstHelicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases (1995) 14:391–399.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Hospital Universitario de la Princesa, Diego de León 62, 28006, Madrid, Spain

    T. Alarcón, D. Domingo, I. Sánchez, J. C. Sanz & M. López-Brea

  2. Department of Gastroenterology, Hospital del Niño Jesús, Madrid, Spain

    M. J. Martínez

Authors
  1. T. Alarcón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Domingo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. C. Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. J. Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. López-Brea
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alarcón, T., Domingo, D., Sánchez, I. et al. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates ofHelicobacter pylori . Eur. J. Clin. Microbiol. Infect. Dis. 17, 275–277 (1998). https://doi.org/10.1007/BF01699986

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01699986

Keywords

Search

Navigation